Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miren Zuazo

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Lung Cancer Management|February 5, 2019
Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapiesHugo Arasanz, Miren Zuazo, Ruth Vera, et al.
Oncotarget|September 9, 2017
PD1 signal transduction pathways in T cellsHugo Arasanz, Maria Gato-Cañas, Miren Zuazo, et al.
Annals of Translational Medicine|November 9, 2017
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapyMiren Zuazo, Maria Gato-Cañas, Noelia Llorente, et al.
EMBO Molecular Medicine|July 11, 2020
Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapyMiren Zuazo, Hugo Arasanz, Ana Bocanegra, et al.
Archivum Immunologiae Et Therapiae Experimentalis|October 17, 2017
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future PerspectivesMaria Ibáñez-Vea, Miren Zuazo, Maria Gato, et al.
Frontiers in Immunology|December 17, 2020
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy EfficacyMiren Zuazo, Hugo Arasanz, Ana Bocanegra, et al.
Signal Transduction and Targeted Therapy|October 3, 2018
The intracellular signalosome of PD-L1 in cancer cellsDavid Escors, María Gato-Cañas, Miren Zuazo, et al.
International Journal of Molecular Sciences|September 13, 2025
Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery VectorsAne Arrasate, Carlos Lopez-Robles, Miren Zuazo, et al.
International Journal of Molecular Sciences|April 5, 2020
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor TherapiesCarlos Hernandez, Hugo Arasanz, Luisa Chocarro, et al.
International Journal of Molecular Sciences|August 23, 2020
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade ImmunotherapyAna Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Lung Cancer Management|February 5, 2019
Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapiesHugo Arasanz, Miren Zuazo, Ruth Vera, et al.
Oncotarget|September 9, 2017
PD1 signal transduction pathways in T cellsHugo Arasanz, Maria Gato-Cañas, Miren Zuazo, et al.
Annals of Translational Medicine|November 9, 2017
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapyMiren Zuazo, Maria Gato-Cañas, Noelia Llorente, et al.
EMBO Molecular Medicine|July 11, 2020
Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapyMiren Zuazo, Hugo Arasanz, Ana Bocanegra, et al.
Archivum Immunologiae Et Therapiae Experimentalis|October 17, 2017
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future PerspectivesMaria Ibáñez-Vea, Miren Zuazo, Maria Gato, et al.
Frontiers in Immunology|December 17, 2020
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy EfficacyMiren Zuazo, Hugo Arasanz, Ana Bocanegra, et al.
Signal Transduction and Targeted Therapy|October 3, 2018
The intracellular signalosome of PD-L1 in cancer cellsDavid Escors, María Gato-Cañas, Miren Zuazo, et al.
International Journal of Molecular Sciences|September 13, 2025
Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery VectorsAne Arrasate, Carlos Lopez-Robles, Miren Zuazo, et al.
International Journal of Molecular Sciences|April 5, 2020
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor TherapiesCarlos Hernandez, Hugo Arasanz, Luisa Chocarro, et al.
International Journal of Molecular Sciences|August 23, 2020
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade ImmunotherapyAna Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, et al.
Pageof 3